Author: Ken Dropiewski

Modern Vascular Appoints Two Key Executives to Lead the Group’s Expanding National Clinical Operations

PHOENIX, Feb. 10, 2020 (GLOBE NEWSWIRE) — Modern Vascular today announced the appointment of two key executives to lead the group’s clinical operations, effective immediately. Dr. Scott Brannan will serve as Chief of Endovascular Surgery, and Dr. Nikhil Patel as Chief Medical Officer. Dr. Brannan was previously the group’s National […]

LeMaitre Vascular Announces Q4 2019 Financial Results

February 6, 2020 at 4:05 PM EST PDF Version BURLINGTON, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) — LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2019 results, provided guidance, and announced a $0.095/share dividend. Q4 2019 Results Record sales of $30.2mm, +6% (flat organic) vs. Q4 2018 Operating income […]

CorMatrix® Cardiovascular, Inc. receives FDA approval to expand and enroll 20 additional patients in the adult arm of its early feasibility IDE study of the Cor® TRICUSPID ECM® valve for pediatric and adult patients

ATLANTA, Feb. 7, 2020 /PRNewswire/ — CorMatrix®Cardiovascular, Inc., a leading developer of regenerative cardiovascular medical devices, today announced receiving FDA approval to expand and enroll 20 additional patients in the adult arm, including up to 4 additional cardiac surgery research and investigative centers, for its early feasibility IDE study of the Cor® TRICUSPID ECM® valve* for […]

Amarin Honored by BioNJ with Innovator Award for VASCEPA® Development and Regulatory Approval

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), announced today that BioNJ awarded Amarin with an Innovator Award in recognition of the approval of a new indication for VASCEPA® (icosapent ethyl) by the U.S. Food and Drug Administration (FDA) in December 2019. This […]

Aria CV Receives FDA Breakthrough Designation for Its Medical Device for Treating Pulmonary Arterial Hypertension

SAINT PAUL, Minn.–(BUSINESS WIRE)–Aria CV, Inc., a developer of medical devices treating Pulmonary Arterial Hypertension (PAH), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the Aria CV Pulmonary Hypertension System (Aria CV PH System). The Breakthrough Devices Program (BDP) is intended to […]

JanOne strikes agreement with CoreRx, a leading cGMP contract manufacturer, for Phase 2b clinical formulation and development

JanOne’s lead drug clinical candidate TV1001SR to treat PAD and associated pain will be manufactured by CoreRX Pharma with phase 2b trials expected to begin Q4 2020 LAS VEGAS, Feb. 6, 2020 /PRNewswire/ — JanOne Inc. (NASDAQ: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs […]